Andrew F Longosz1, Shruti H Mehta, Gregory D Kirk, Joseph B Margolick, Joelle Brown, Thomas C Quinn, Susan H Eshleman, Oliver Laeyendecker. 1. aLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH bDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health cDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland dDepartment of Epidemiology, School of Public Health, University of California at Los Angeles, Los Angeles, California eDepartment of Medicine fDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
OBJECTIVES: To evaluate factors associated with misclassification by the limiting-antigen avidity (LAg-avidity) assay among individuals with long-standing HIV infection. DESIGN: Samples were obtained from the Multicenter AIDS Cohort Study and AIDS Linked to the IntraVenous Experience cohort (1089 samples from 667 individuals, 595 samples collected 2-4 years and 494 samples collected 4-8 years after HIV seroconversion). Paired samples from both time points were available for 422 (63.3%) of the 667 individuals. METHODS: Samples were considered to be misclassified if the LAg-avidity assay result was 1.5 or less normalized optical density (OD-n) units. RESULTS: Overall, 4.8% (52/1089) of the samples were misclassified, including 1.8% [16/884, 95% confidence interval (CI) 1.09-3.06%] of samples from individuals with viral loads above 400 copies/ml and 1.4% (10/705) of samples from individuals with viral loads above 400 copies/ml and CD4 cell counts above 200 cells/μl (95% CI 0.68-2.60%). Age, race, sex, and mode of HIV acquisition were not associated with misclassification. In an adjusted analysis, viral load below 400 copies/ml [adjusted odds ratio (aOR) 3.72, 95% CI 1.61-8.57], CD4 cell count below 50 cells/μl (aOR 5.41, 95% CI 1.86-15.74), and low LAg-avidity result (≤1.5 OD-n) from the earlier time point (aOR 5.60, 95% CI 1.55-20.25) were significantly associated with misclassification. CONCLUSIONS: The manufacturer of the LAg-avidity assay recommends excluding individuals from incidence surveys who are receiving antiretroviral therapy, are elite suppressors, or have AIDS (CD4 cell count <200 cells/μl). The results of this study indicate that those exclusions do not remove all sources of assay misclassification among individuals with long-standing HIV infection.
OBJECTIVES: To evaluate factors associated with misclassification by the limiting-antigen avidity (LAg-avidity) assay among individuals with long-standing HIV infection. DESIGN: Samples were obtained from the Multicenter AIDS Cohort Study and AIDS Linked to the IntraVenous Experience cohort (1089 samples from 667 individuals, 595 samples collected 2-4 years and 494 samples collected 4-8 years after HIV seroconversion). Paired samples from both time points were available for 422 (63.3%) of the 667 individuals. METHODS: Samples were considered to be misclassified if the LAg-avidity assay result was 1.5 or less normalized optical density (OD-n) units. RESULTS: Overall, 4.8% (52/1089) of the samples were misclassified, including 1.8% [16/884, 95% confidence interval (CI) 1.09-3.06%] of samples from individuals with viral loads above 400 copies/ml and 1.4% (10/705) of samples from individuals with viral loads above 400 copies/ml and CD4 cell counts above 200 cells/μl (95% CI 0.68-2.60%). Age, race, sex, and mode of HIV acquisition were not associated with misclassification. In an adjusted analysis, viral load below 400 copies/ml [adjusted odds ratio (aOR) 3.72, 95% CI 1.61-8.57], CD4 cell count below 50 cells/μl (aOR 5.41, 95% CI 1.86-15.74), and low LAg-avidity result (≤1.5 OD-n) from the earlier time point (aOR 5.60, 95% CI 1.55-20.25) were significantly associated with misclassification. CONCLUSIONS: The manufacturer of the LAg-avidity assay recommends excluding individuals from incidence surveys who are receiving antiretroviral therapy, are elite suppressors, or have AIDS (CD4 cell count <200 cells/μl). The results of this study indicate that those exclusions do not remove all sources of assay misclassification among individuals with long-standing HIV infection.
Authors: Edmore T Marinda; John Hargrove; Wolfgang Preiser; Hannes Slabbert; Gert van Zyl; Jonathan Levin; Lawrence H Moulton; Alex Welte; Jean Humphrey Journal: J Acquir Immune Defic Syndr Date: 2010-04-01 Impact factor: 3.731
Authors: Till Bärnighausen; Thomas A McWalter; Zachary Rosner; Marie-Louise Newell; Alex Welte Journal: Epidemiology Date: 2010-09 Impact factor: 4.822
Authors: Caroline E Mullis; Supriya Munshaw; Mary K Grabowski; Susan H Eshleman; David Serwadda; Ronald Brookmeyer; Fred Nalugoda; Godfrey Kigozi; Joseph Kagaayi; Aaron A R Tobian; Maria Wawer; Ronald H Gray; Thomas C Quinn; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2013-05-29 Impact factor: 2.205
Authors: Jessica M Fogel; Estelle Piwowar-Manning; Kelsey Donohue; Vanessa Cummings; Mark A Marzinke; William Clarke; Autumn Breaud; Agnès Fiamma; Deborah Donnell; Michal Kulich; Jessie K K Mbwambo; Linda Richter; Glenda Gray; Michael Sweat; Thomas J Coates; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: Sarah K Wendel; Andrew F Longosz; Susan H Eshleman; Joel N Blankson; Richard D Moore; Jeanne C Keruly; Thomas C Quinn; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2017-01-11 Impact factor: 2.205
Authors: Anna L Eisenberg; Eshan U Patel; Zoe R Packman; Reinaldo E Fernandez; Estelle Piwowar-Manning; Erica L Hamilton; Catherine MacPhail; James Hughes; Audrey Pettifor; Esper G Kallas; Michael P Busch; Gary Murphy; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2018-10-17 Impact factor: 2.205
Authors: Briana A Lynch; Eshan U Patel; Colleen R Courtney; Aubin J Nanfack; Jude Bimela; Xiaohong Wang; Issa Eid; Thomas C Quinn; Oliver Laeyendecker; Phillipe N Nyambi; Ralf Duerr; Andrew D Redd Journal: AIDS Res Hum Retroviruses Date: 2017-08-07 Impact factor: 2.205
Authors: Allison R Kirkpatrick; Eshan U Patel; Connie L Celum; Richard D Moore; Joel N Blankson; Shruti H Mehta; Gregory D Kirk; Joseph B Margolick; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2016-05-05 Impact factor: 2.205
Authors: Ethan Klock; George Mwinnya; Leigh Anne Eller; Reinaldo E Fernandez; Hannah Kibuuka; Sorachai Nitayaphan; Josphat Kosgei; Richard D Moore; Merlin Robb; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2020-05-27 Impact factor: 2.205
Authors: Reshma Kassanjee; Christopher D Pilcher; Michael P Busch; Gary Murphy; Shelley N Facente; Sheila M Keating; Elaine Mckinney; Kara Marson; Matthew A Price; Jeffrey N Martin; Susan J Little; Frederick M Hecht; Esper G Kallas; Alex Welte Journal: AIDS Date: 2016-09-24 Impact factor: 4.177